Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
4 minute read
  • Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights
Today, 6:54 AM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

BDX

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Goldman Sachs Maintains Buy on Becton, Dickinson, Lowers Price Target to $272

By Benzinga Newsdesk
Today, 6:54 AM
Goldman Sachs analyst Amit Hazan maintains Becton, Dickinson (NYSE:BDX) with a Buy and lowers the price target from $319 to $272.

BDX

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Piper Sandler Maintains Neutral on Becton, Dickinson, Lowers Price Target to $245

By Benzinga Newsdesk
Today, 6:54 AM
Piper Sandler analyst Jason Bednar maintains Becton, Dickinson (NYSE:BDX) with a Neutral and lowers the price target from $255 to $245.

BDX

Read More
2 minute read
  • General
  • Health Care
  • News

BD And Magnolia Medical Technologies To Co-Sell And Co-Market Magnolia’s Steripath And Steripath Micro Initial Specimen Diversion Device Platforms

By Benzinga Newsdesk
Today, 6:54 AM
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and Magnolia Medical Technologies, Inc., today announced a co-exclusive commercial agreement aimed at helping U.S. hospitals

BDX

Read More
1 minute read
  • Analyst Ratings
  • Markets
  • News
  • Price Target
  • Trading Ideas

Becton Dickinson To Rally 23%? This Analyst Predicts $210 For NVIDIA

By Lisa Levin
Today, 6:54 AM
Citigroup cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $248 to $210. NVIDIA shares rose 1.2% to $118.12 on Tuesday.

AOS

Read More
47 minute read
  • Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights
Today, 6:54 AM
  On Tuesday, 838 companies hit new 52-week lows.

$APE

Read More
1 minute read
  • News

Becton Dickinson Recalls Surgical-tool Sterilization Containers Over Potential Breaches

By Benzinga Newsdesk
Today, 6:54 AM
-Wall Street Journal

BDX

Read More
1 minute read
  • FDA
  • General
  • Health Care
  • News

FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests

By Vandana Singh
Today, 6:54 AM
The FDA said it will now review only a small number of emergency use authorization (EUA) requests for COVID-19 diagnostic…

A

Read More
2 minute read
  • Biotech
  • General
  • News

BD, CerTest Biotec Announce US Commercial Launch Of Monkeypox Assay

By Benzinga Newsdesk
Today, 6:54 AM
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and CerTest Biotec today announced their newly developed molecular polymerase chain reaction (PCR) assay for monkeypox virus is

BDX

Read More
1 minute read
  • Dividends
  • Earnings
  • News

If You Invested $100 In This Stock 15 Years Ago, You Would Have $300 Today

By Benzinga Insights
Today, 6:54 AM
Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 15 years by 1.67% on an annualized basis producing an average annual return of 8.44%. Currently, Becton, Dickinson has a market capitalization of $73.87 billion.

BDX

Posts navigation

Previous 1 2 3 … 10 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service